

**Amendments to the Claims:**

1. (Original) A fusion partner protein comprising a choline binding domain and a heterologous promiscuous T helper epitope.
2. (Original) A fusion partner protein according to claim 1 wherein the choline binding domain is derived from the C terminus of LytA.
3. (Original) A fusion partner protein according to claim 2 wherein the C-LytA or derivatives comprises at least four repeats of any of SEQ ID NO:1 to 6.
4. (Currently Amended) A fusion partner protein according to ~~any of claims 1 to 3~~ claim 1, wherein the choline binding domain is selected from the group of ~~comprising~~:
  - a) the C-terminal domain of LytA as set forth in SEQ ID NO:7; ~~or~~
  - b) the sequence of SEQ ID NO:8; ~~or~~
  - c) a peptide sequence comprising an amino acid sequence having at least 85% identity, ~~preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity~~, to any of SEQ ID NO:1 to 6; and ~~or~~
  - d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.
5. (Currently Amended) A fusion partner protein as claimed in ~~any of claims 1 to 4~~ claim 1 further comprising a heterologous protein.
6. (Original) A fusion protein as claimed in claim 5 wherein the heterologous protein is chemically conjugated the fusion partner.
7. (Currently Amended) A fusion protein as claimed in claim 5 ~~or 6~~ wherein the heterologous protein is derived from an organism selected from the following group: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, ~~from a hepatitis virus such as hepatitis B virus~~, hepatitis A virus, hepatitis C virus, and hepatitis E virus, from Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses, and ~~or~~ Influenza virus, from *Neisseria spp*, *Moraxella spp*, *Bordetella spp*; *Mycobacterium spp*,

~~including~~ *M. tuberculosis*; *Escherichia* spp, ~~including~~ enterotoxigenic *E. coli*; *Salmonella* spp.; *Listeria* spp; *Helicobacter* spp; *Staphylococcus* spp., ~~including~~ *S. aureus*, *S. epidermidis*; *Borrelia* spp; *Chlamydia* spp., ~~including~~ *C. trachomatis*, *C. pneumoniae*; *Plasmodium* spp., ~~including~~ *P. falciparum*; *Toxoplasma* spp., or *Candida* spp.

8. (Currently Amended) A fusion protein as claimed in claim 5 ~~or 6~~ wherein the heterologous protein is a tumour associated protein or tissue specific protein or immunogenic fragment thereof.
9. (Original) A fusion protein as claimed in claim 8 wherein the heterologous protein or fragment thereof is selected from MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostatein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, or her 2 neu.
10. (Currently Amended) A fusion protein as claimed in ~~any of claims 6 to 9~~ claim 6 further comprising an affinity tag of at least 4 histidine residues.
11. (Currently Amended) A nucleic acid sequence encoding a protein of claim 1 ~~to 10~~.
12. (Original) An expression vector comprising a nucleic acid sequence of claim 11.
13. (Currently Amended) A host cell transformed with ~~a nucleic acid sequence of claim 11 or with~~ an expression vector of claim 12.
14. (Currently Amended) An immunogenic composition comprising a protein as claimed in ~~any of claim 1 to 10 or a DNA sequence as claimed in claim 11~~ and a pharmaceutically acceptable excipient.
15. (Original) An immunogenic composition as claimed in claim 14 which additionally comprises a TH-1 inducing adjuvant.
16. (Original) An immunogenic composition as claimed in claim 15 in which the TH-1 inducing adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide or a mixture of two or more said adjuvants.
17. (Currently Amended) A process for the preparation of a immunogenic composition ~~as claimed in any of claims 14 to 16~~, comprising admixing the fusion

protein of claim 6 ~~any of claims 6 to 10 or a the encoding polynucleotide of claim 11~~ with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.

18. (Currently Amended) A process for producing a fusion protein of claim 1 ~~any of claims 1 to 10~~ comprising culturing a host cell comprising a vector encoding said fusion protein of claim 13 under conditions sufficient for the production of said fusion protein and recovering the fusion protein from the culture medium.

19. (Currently Amended) A pharmaceutical composition comprising a fusion A protein of claim 1 ~~any of claims 1 to 10 or a DNA sequence of claim 11~~ for use in medicine.

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Original) A method of treating a patient suffering from cancer by administering a safe and effective amount of a composition according to claim 12.

27. (Original) A method according to claim 26 wherein said cancer is prostate cancer, colorectal cancer, lung cancer, breast cancer or melanoma.

28. (New) An immunogenic composition comprising a DNA sequence as claimed in claim 11 and a pharmaceutically acceptable excipient.

29. (New) A process for the preparation of an immunogenic composition, comprising admixing the fusion protein of a polynucleotide of claim 11 with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.

30. (New) A method of eliciting an immune response in a patient comprising administering an immunogenic composition of claim 14.

31. (New) The method according to claim 30, wherein said immune response is to be elicited by sequential administration of i) the said protein followed by a nucleic acid encoding said protein; or ii) a nucleic acid encoding said protein followed by said protein.

- 32. (New) The method according to claim 31 wherein said nucleic acid sequence is coated onto biodegradable beads or delivered via a particle bombardment approach.
- 33. (New) The method according to claim 31 wherein said protein is adjuvanted.
- 34. (New) The method according to claim 31 wherein the patient is suffering from or susceptible to cancer.
- 35. (New) The method according to claim 34 wherein said cancer is prostate cancer, colon cancer, lung cancer, breast cancer or melanoma.